BMBaha Moshiree

Baha Moshiree

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Baha Moshiree has a total of 137 co-authors. Here are the top co-authors by number of shared publications:

  • Satish Sanku Chander Rao

    Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, Georgia, USA

    3 shared publications
  • Anthony Lembo

    Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA

    2 shared publications
  • Christopher H. Goss

    Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle WA, United States; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States; Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States

    2 shared publications
  • Irene Sarosiek

    Texas Tech University Health Science Center El Paso Texas USA

    2 shared publications
  • Jason Baker

    Atrium Health Wake Forest Medical University, Charlotte, North Carolina, USA

    2 shared publications
  • John M. Wo

    Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA

    2 shared publications

Latest Publications

  • Abelchia: A Clinical Review of Retrograde Cricopharyngeus Dysfunction and Inability to Belch for Gastroenterologists

    by Chethan Ramprasad, C. Prakash Gyawali, Baha Moshiree, Adrianna Wierzbicka, Ofer Fass, Anthony Lembo, Vikram Rangan, Sarah Ballou, Trisha Pasricha, Stephanie E. Teng, et al.

    Abelchia, also termed the inability to belch syndrome, is an increasingly recognized upper esophageal sphincter (UES) disorder characterized by retrograde cricopharyngeal dysfunction (RCPD). This disorder is highly relevant to gastroenterologists since presentation consists of common upper gastrointestinal symptoms including chest pain, gurgling noises in the chest, abdominal pressure, and bloating, often misattributed to alternate foregut disorders. Abelchia is thought to result from absent or incomplete UES relaxation in response to retrograde esophageal air distension, causing esophageal air trapping, despite preserved anterograde swallowing-related UES relaxation. The diagnosis is suspected based on clinical presentation and absence of alternate esophageal structural/motor disorders and supported by high-resolution impedance manometry with carbonated beverage challenge. Injection of botulinum toxin into the UES during rigid esophagoscopy is the mainstay of treatment, though data supporting this are largely derived from case series. Symptom benefit typically outlasts the general duration of efficacy of botulinum toxin, suggesting retraining of retrograde UES relaxation and the ability to belch. Consequently, behavioral therapy has been also reported to be of benefit. Randomized trials, standardized diagnostic criteria, and long-term outcome studies are lacking. This review summarizes the evolving literature on abelchia with emphasis on clinical presentation, diagnostic evaluation, differential diagnosis, treatment, and the role of gastroenterologists in identifying this underrecognized disorder.

  • Impact of Constipation Therapies on Severity of Gastroparesis and Constipation Symptoms in Relation to Gastric and Colonic Transit

    by Brian C. Surjanhata, Baharak Moshiree, Allen A. Lee, Richard W. McCallum, Irene Sarosiek, Linda A. Nguyen, Michael I. Schulman, John M. Wo, Henry P. Parkman, Braden Kuo, et al.

    Introduction: Studies demonstrate an overlap of constipation with gastroparesis and functional dyspepsia, but the impact of treatments that target constipation on improving upper gastrointestinal (UGI) symptoms is unexplored. We quantified the effects of constipation medication therapies on UGI and constipation symptom severity in subjects presenting with symptoms of gastroparesis.Methods: Fifty‐six subjects with symptoms of gastroparesis underwent concurrent wireless motility capsule and gastric emptying scintigraphy and were recommended to receive either a new medication therapy for constipation or a change in constipation therapy based on investigator interpretation of test results. Gastroparesis Cardinal Symptom Index (GCSI), upper abdominal pain, and constipation scores were compared between baseline and 6 months. Data were compared between delayed or non‐delayed gastric emptying and the presence or absence of slow colonic transit.Key Results: Subjects with slow colonic transit had improvements in GCSI (p = 0.007) and constipation scores (p = 0.004) after treatment with a new or changed constipation medication, with the delayed emptying subgroup driving GCSI improvements (p = 0.004). Reductions in nausea/vomiting (p = 0.02) and early satiety/fullness subscores (p = 0.002) with trends to improved bloating/distention subscores (p = 0.06) were observed in this subgroup, but upper abdominal pain was unchanged. Subjects with normal colonic transit showed no improvement in GCSI scores regardless of gastric emptying status (p > 0.05).Conclusions and Inferences: Identifying and treating delayed colonic transit in gastroparetic (delayed gastric emptying) subjects improves global UGI symptoms as well as selected individual symptoms. Evaluation of whole gut motility as well as recognizing and managing extragastric delay may promote improved outcomes in these patients.Trial Registration: ClinicalTrials.gov: NCT02022826


  • Prevalence and Clinical Impact of the London Classification: A Prospective, International, Multicenter Study From the Lower Gastrointestinal International Consortium (LoGIC)

    by Paul F. Vollebregt, Paul T. Heitmann, Henri Damon, Karla Garcia-Zermeño, Fausto Daniel Garcia, Jason Baker, Ann Schloithe, Baharak Moshiree, Jose M. Remes-Troche, François Mion, et al.

    INTRODUCTION: The London classification provides standardization for characterization of disorders of anorectal function, although prevalences and clinical impact of these disorders are unclear. METHODS: An international research consortium was established, including 5 specialist centers. Prospective data were collected in consecutive adults referred for refractory chronic constipation (CC), fecal incontinence (FI), or coexistent CC/FI over 18 months. Patients completed a standardized clinical questionnaire and underwent anorectal physiology tests, which were performed and interpreted using uniform methodology. The prevalence of the London classification was compared between symptom groups (CC, FI, and coexistent CC/FI), equipment types, and sites. Clinical impact was assessed using Cleveland Clinic Constipation and St. Marks Incontinence Scores. RESULTS: Of 1,012 included patients (85.6% women), 30.5% had self-reported CC, 33.2% had FI, and 36.3% had coexistent CC/FI. Rectoanal areflexia was uncommon (3.1%). Disorders of anal tone/contractility (CC: 45.0%; FI: 68.5%; coexistent CC/FI: 63.8%; P < 0.0001) and disorders of rectal sensation (major findings: rectal hyposensitivity, CC: 10.0%; FI: 5.0%; coexistent CC/FI: 11.1%; P = 0.018; rectal hypersensitivity, CC: 3.8%; FI: 9.0%; coexistent CC/FI: 4.9%; P = 0.025) varied between the symptom groups and were associated with symptom severity. Most disorders of rectoanal coordination were found in similar proportions across the symptom groups and were not associated with the severity of CC (median Cleveland Clinic Constipation Score 10–14 in all groups). Prevalences of some disorders differed between equipment types (specifically balloon expulsion test). DISCUSSION: This prospective multicenter study provides information on the prevalence and clinical impact of the London classification and will guide refinement of the current London classification.


  • Evaluation of a Novel Smart Capsule Bacterial Detection System Device for Diagnosis of Small Intestinal Bacterial Overgrowth

    by Shaoying Nikki Lee, Pejman Rahimian, Cheryl Stork, Baharak Moshiree, Mitchell Jones, Emil Chuang, Chris Wahl, Sharat Singh, Satish S. C. Rao

    Background: There is a large unmet need for alternative, non‐invasive, and accurate diagnosis of small intestinal bacterial overgrowth (SIBO). The smart capsule bacterial detection system (SCBDS) device contains a targeted sampling technology and an onboard SCBDS assay to detect metabolically active bacteria in the small intestine. Here, we evaluated the agreement of SCBDS assay with duodenal aspiration/culture ex vivo in a multicenter clinical study.Methods: Duodenal aspiration was performed in subjects with gastrointestinal symptoms suggestive of SIBO. Aspirated fluid was sent to local and central microbiology labs to evaluate the agreement for detecting bacteria with SCBDS assay compared to the total bacterial count (TBC) reference standard. The performance of SCBDS assay was evaluated using a receiver operator curve, sensitivities, and specificities.Key Results: Aspirates from 66 patients were collected and analyzed for TBC and SCDBS assay. The overall agreement between the two assays was 82%–92% across 3 clinical sites. The SCBDS assay had a sensitivity of 67%–100% and a specificity of 90%–97% using either ≥ 103 or 105 CFU mL−1 cutoff. Additionally, there was a good correlation (r = 0.82) for the TBC culture between the local and central labs.Conclusions and Inferences: The SCBDS assay showed a high level of agreement with TBC and improved performance compared to other non‐invasive tests. These results demonstrate the potential utility of SCBDS device to aid SIBO diagnosis as a simple and non‐invasive tool that merits further clinical validation.


  • A systematic review of yoga for the treatment of gastrointestinal disorders

    by Elyse R. Thakur, Jordan M. Shapiro, Jennifer Wellington, Stephanie J. Sohl, Suzanne C. Danhauer, Baharak Moshiree, Alexander C. Ford, Kenneth Koch

    Background: Several studies have reviewed yoga for the treatment of disorders of gut‐brain interaction (DGBI) with most demonstrating a benefit for symptom reduction; however, yoga has been studied beyond DGBI. Purpose: The aim of this systematic review is to provide a comprehensive summary of yoga as treatment for gastrointestinal conditions. Method: We conducted literature searches in PubMed and Embase and included yoga trials of adults with a diagnosis of a gastrointestinal disorders and diseases. Results: We identified 1275 articles; 12 studies were eligible. Most studies compared yoga to controls, for patients with different GI conditions (irritable bowel syndrome, ulcerative colitis, chronic pancreatitis, and gastrointestinal cancer). The type, method, and duration of yoga used varied. Across IBS studies, most demonstrated that yoga improved IBS symptom severity, mood‐related symptoms, and quality of life compared with controls. In one study of inflammatory bowel disease, yoga improved quality of life compared to controls. Two studies of gastrointestinal cancer demonstrated that yoga led to a reduction in sleep disturbance and mood symptoms. One study of chronic pancreatitis found that yoga led to improvements in quality of life, stress, mood changes, alcohol dependence, and appetite. Yoga was generally safe, and no serious adverse events were attributed to the intervention. Conclusion: In conclusion, yoga appears to be safe and has potential to improve functioning across a spectrum of gastrointestinal diseases; however, current studies are limited by heterogeneity and methodological weaknesses. Further research is needed to evaluate the impact of yoga on health outcomes for a broader range of gastrointestinal conditions.


  • Open Access

    Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States

    by Morgan Allyn Sendzischew Shane, Johannah Ruddy, Michael Cline, David P Rosenbaum, Susan Edelstein, Baharak Moshiree

    Irritable bowel syndrome (IBS) is a common disorder of the gut–brain axis. IBS with constipation (IBS-C) accounts for approximately one-third of IBS cases and is associated with substantial burden of illness and decreased quality of life. This narrative review provides an overview of the current and upcoming treatment options and disease management for IBS-C from a US perspective and discusses the importance of the relationship between patient and health care provider in diagnosis and treatment. A positive diagnostic strategy for IBS-C is recommended, based on clinical history, physical examination, and minimal laboratory tests. An effective communication strategy between patients and health care professionals is essential to ensure early diagnosis and reduce both health care costs and overall disease burden. Treatment typically begins with lifestyle interventions and nonpharmacologic options, such as dietary interventions, fiber supplements, and osmotic laxatives. In patients with inadequate response to these therapies, 4 currently available therapies (lubiprostone, linaclotide, plecanatide, and tenapanor) approved by the US Food and Drug Administration may relieve IBS-C symptoms. These agents are generally well tolerated and efficacious in improving IBS-C symptoms, including constipation and abdominal pain. In patients with persistent abdominal pain and/or psychological symptoms, brain–gut behavioral therapy or neuromodulator therapy may be beneficial.


  • Open Access

    Predicting Response to Neuromodulators or Prokinetics in Patients With Suspected Gastroparesis Using Machine Learning: The “BMI, Infectious Prodrome, Delayed GES, and No Diabetes” Model

    by Will Takakura, Brian Surjanhata, Linda Anh Bui Nguyen, Henry P. Parkman, Satish S.C. Rao, Richard W. McCallum, Michael Schulman, John Man-Ho Wo, Irene Sarosiek, Baha Moshiree, et al.

    INTRODUCTION: Pharmacologic therapies for symptoms of gastroparesis (GP) have limited efficacy, and it is difficult to predict which patients will respond. In this study, we implemented a machine learning model to predict the response to prokinetics and/or neuromodulators in patients with GP-like symptoms. METHODS: Subjects with suspected GP underwent simultaneous gastric emptying scintigraphy (GES) and wireless motility capsule and were followed for 6 months. Subjects were included if they were started on neuromodulators and/or prokinetics. Subjects were considered responders if their GP Cardinal Symptom Index at 6 months decreased by ≥1 from baseline. A machine learning model was trained using lasso regression, ridge regression, or random forest. Five-fold cross-validation was used to train the models, and the area under the receiver operator characteristic curve (AUC-ROC) was calculated using the test set. RESULTS: Of the 150 patients enrolled, 123 patients received either a prokinetic and/or a neuromodulator. Of the 123, 45 were considered responders and 78 were nonresponders. A ridge regression model with the variables, such as body mass index, infectious prodrome, delayed gastric emptying scintigraphy, no diabetes, had the highest AUC-ROC of 0.72. The model performed well for subjects on prokinetics without neuromodulators (AUC-ROC of 0.83) but poorly for those on neuromodulators without prokinetics. A separate model with gastric emptying time, duodenal motility index, no diabetes, and functional dyspepsia performed better (AUC-ROC of 0.75). DISCUSSION: This machine learning model has an acceptable accuracy in predicting those who will respond to neuromodulators and/or prokinetics. If validated, our model provides valuable data in predicting treatment outcomes in patients with GP-like symptoms.


  • Open Access

    Gastric Emptying Scintigraphy Protocol Optimization Using Machine Learning for the Detection of Delayed Gastric Emptying

    by Michalis F. Georgiou, Efrosyni Sfakianaki, Monica N. Diaz-Kanelidis, Baha Moshiree

    Purpose: The purpose of this study is to examine the feasibility of a machine learning (ML) system for optimizing a gastric emptying scintigraphy (GES) protocol for the detection of delayed gastric emptying (GE), which is considered a primary indication for the diagnosis of gastroparesis. Methods: An ML model was developed using the JADBio AutoML artificial intelligence (AI) platform. This model employs the percent GE at various imaging time points following the ingestion of a standardized radiolabeled meal to predict normal versus delayed GE at the conclusion of the 4 h GES study. The model was trained and tested on a cohort of 1002 patients who underwent GES using a 70/30 stratified split ratio for training vs. testing. The ML software automated the generation of optimal predictive models by employing a combination of data preprocessing, appropriate feature selection, and predictive modeling analysis algorithms. Results: The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was employed to evaluate the predictive modeling performance. Several models were developed using different combinations of imaging time points as input features and methodologies to achieve optimal output. By using GE values at time points 0.5 h, 1 h, 1.5 h, 2 h, and 2.5 h as input predictors of the 4 h outcome, the analysis produced an AUC of 90.7% and a balanced accuracy (BA) of 80.0% on the test set. This performance was comparable to the training set results (AUC = 91.5%, BA = 84.7%) within the 95% confidence interval (CI), demonstrating a robust predictive capability. Through feature selection, it was discovered that the 2.5 h GE value alone was statistically significant enough to predict the 4 h outcome independently, with a slightly increased test set performance (AUC = 92.4%, BA = 83.3%), thus emphasizing its dominance as the primary predictor for delayed GE. ROC analysis was also performed for single time imaging points at 1 h and 2 h to assess their independent predictiveness of the 4 h outcome. Furthermore, the ML model was tested for its ability to predict “flipping” cases with normal GE at 1 h and 2 h that became abnormal with delayed GE at 4 h. Conclusions: An AI/ML model was designed and trained for predicting delayed GE using a limited number of imaging time points in a 4 h GES clinical protocol. This study demonstrates the feasibility of employing ML for GES optimization in the detection of delayed GE and potentially shortening the protocol’s time length without compromising diagnostic power.


  • Open Access

    Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States

    by Anthony Lembo, Brooks D. Cash, Mei Lu, Emi Terasawa, Brian Terreri, Shawn Du, Rajeev Ayyagari, Paul Feuerstadt, Baharak Moshiree, Ben Westermeyer, et al.

    INTRODUCTION: This real-world US-based claims study compared constipation-related symptoms and complications 6 months before and after prucalopride initiation in adults with chronic idiopathic constipation (CIC). METHODS: This observational, retrospective cohort analysis used the IBM MarketScan Commercial Claims and Encounters Database and the Medicare Supplemental Database (January 2015–June 2020). Prucalopride-treated patients (≥18 years old) who had ≥1 constipation-related International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code during the baseline or study period were included. The proportions of patients with constipation-related symptoms (abdominal pain, abdominal distension [gaseous], incomplete defecation, and nausea) and constipation-related complications (anal fissure and fistula, intestinal obstruction, rectal prolapse, hemorrhoids, perianal venous thrombosis, perianal/perirectal abscess, and rectal bleeding) were examined. Constipation-related symptoms and complications were identified using ICD-10-CM, ICD-10-Procedure Coding System, or Current Procedural Terminology codes. Data were stratified by age (overall, 18–64 years, and ≥65 years). RESULTS: This study included 690 patients: The mean (SD) patient age was 48.0 (14.7) years, and 87.5% were women. The proportions of patients overall with constipation-related symptoms decreased 6 months after prucalopride initiation (abdominal pain [50.4% vs 33.3%, P < 0.001]; abdominal distension [gaseous] [23.9% vs 13.3%, P < 0.001]; and nausea [22.6% vs 17.7%, P < 0.01]; no improvements observed for incomplete defecation). Similarly, the proportions of patients overall with constipation-related complications decreased 6 months after prucalopride initiation (intestinal obstruction [4.9% vs 2.0%, P < 0.001]; hemorrhoids [10.7% vs 7.0%, P < 0.05]; and rectal bleeding [4.1% vs 1.7%, P < 0.05]). DISCUSSION: This study suggests that prucalopride may be associated with improved constipation-related symptoms and complications 6 months after treatment initiation.


  • The Time-Dependent Association Between Irritable Bowel Syndrome and All-Cause and Cause-Specific Mortality: A Prospective Cohort Study Within the UK Biobank

    by Fangyu Li, Yukiko Yano, Lola Étiévant, Carrie R. Daniel, Shreela V. Sharma, Eric L. Brown, Ruosha Li, Erikka Loftfield, Qing Lan, Rashmi Sinha, et al.

    INTRODUCTION: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, but few studies have evaluated mortality risks among individuals with IBS. We explored the association between IBS and all-cause and cause-specific mortality in the UK Biobank. METHODS: We included 502,369 participants from the UK Biobank with mortality data through 2022. IBS was defined using baseline self-report and linkage to primary care or hospital admission data. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause and cause-specific mortality using multivariable Cox proportional hazards regression models within partitioned follow-up time categories (0–5, >5–10, and >10 years). RESULTS: A total of 25,697 participants (5.1%) had a history of IBS at baseline. After a median follow-up of 13.7 years, a total of 44,499 deaths occurred. Having an IBS diagnosis was strongly associated with lower risks of all-cause (HR = 0.70, 95% CI = 0.62–0.78) and all-cancer (HR = 0.69, 95% CI = 0.60–0.79) mortality in the first 5 years of follow-up. These associations were attenuated over follow-up, but even after 10 years of follow-up, associations remained inverse (all-cause: HR = 0.89, 95% CI = 0.84–0.96; all-cancer: HR = 0.87, 95% CI = 0.78–0.97) after full adjustment. Individuals with IBS had decreased risk of mortality from breast, prostate, and colorectal cancers in some of the follow-up time categories. DISCUSSION: We found that earlier during follow-up, having diagnosed IBS was associated with lower mortality risk, and the association attenuated over time. Additional studies to understand whether specific factors, such as lifestyle and healthcare access, explain the inverse association between IBS and mortality are needed.